Skopos Labs, Inc. Ascendis Pharma A/S Transaction History
Skopos Labs, Inc.
- $330 Million
- Q4 2024
A detailed history of Skopos Labs, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Skopos Labs, Inc. holds 82 shares of ASND stock, worth $10,506. This represents 0.0% of its overall portfolio holdings.
Number of Shares
82Holding current value
$10,506% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ASND
# of Institutions
243Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.24 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$658 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$639 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$565 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$536 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.15B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...